Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
نویسنده
چکیده
s+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=33295; cited March 30, 2009]4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U on behalf of the Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–7. 5. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-lifeadjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using Intergroup clinical trial data. J Clin Oncol 2002;20:1311–18. 6. Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112:982–94. 7. Garbe C, Schadendorf D, Stolz W, et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008; (suppl 1):S9–14. 8. Garbe C, Hauschild A, Volkenandt M, et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008;18:152–60. 9. Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905–10. 10. Dummer R, Hauschild A, Jost L, on behalf of the esmo Guidelines Working Group. Cutaneous malignant melanoma: esmo clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2008;19(suppl 2):ii86–8. 11. Eggermont AM, Suciu S, Santinami M, et al. on behalf of the eortc Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage iii melanoma: final results of eortc 18991, a randomised phase iii trial. Lancet 2008;372:117–26. 12. Sondak VK, Flaherty LE. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we’ve been waiting for? Lancet 2008;372:89–90. 13. Eggermont AM, Suciu S, MacKie R, et al. on behalf of the eortc Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage iib/iii melanoma (eortc 18952): randomised controlled trial. Lancet 2005;366:1189–96. 14. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709–18. 15. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer
منابع مشابه
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
INTRODUCTION Stage III melanoma, also referred to as regional metastatic melanoma, has five-year survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this high-risk population, patients undergo resection of primary tumors and all involved nodal basins. Systemic therapy is being pursued in an effort to improve outcome data, but the best strategy has yet ...
متن کاملUpdate on PEG-interferon α-2b as adjuvant therapy in melanoma.
Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment w...
متن کاملAdjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
High-dose interferon-alpha remains the first-line treatment in the adjuvant therapy of metastatic melanoma. More recently, high-dose pegylated interferon-alpha-2b has been approved by the US Food and Drug Administration. Actually, an adjuvant therapy alternative to high-dose interferon-alpha is represented by ipilimumab. Moreover, combination therapy of IFN-alpha or ipilimumab with tyrosine kin...
متن کاملMalignant melanoma--future prospects.
As the incidence and already high mortality rates of malignant melanoma have been steadily increasing in recent decades, the early detection and excision of malignant melanoma have imposed as the most important task. Staging of malignant melanoma is determined according to the level of invasion (Clark level) and vertical thickness (Breslow scale). Besides operative therapy, which is the only ef...
متن کاملUpdate on adjuvant interferon therapy for high-risk melanoma.
Melanoma is almost 100% curable when diagnosed early, but when metastatic to distant organs, it is associated with a poor survival. The interferons have shown the mostpromise in the treatment of melanoma and interferon-alpha has been the most extensively studied. In recent trials, interferon alfa-2b (Intron A) administered at maximally tolerated doses for 1 year produced improvements in both re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current Oncology
دوره 16 شماره
صفحات -
تاریخ انتشار 2009